Bacillus Calmette–Guérin-induced trained immunity protects against SARS-CoV-2 challenge in K18-hACE2 mice
Bao-Zhong Zhang,Huiping Shuai,Hua-rui Gong,Jing-Chu Hu,Bingpeng Yan,Terrence Tsz-Tai Yuen,Ye-Fan Hu,Chaemin Yoon,Xiao-Lei Wang,Yuxin Hou,Xuansheng Lin,Xiner Huang,Renhao Li,Yee Man Au-Yeung,Wenjun Li,Bingjie Hu,Yue Chai,Ming Yue,Jian-Piao Cai,Guang Sheng Ling,Ivan Fan-Ngai Hung,Kwok-Yung Yuen,Jasper Fuk-Woo Chan,Jian-Dong Huang,Hin Chu
DOI: https://doi.org/10.1172/jci.insight.157393
IF: 9.4958
2022-04-21
JCI Insight
Abstract:SARS-CoV-2 has been confirmed in over 450 million confirmed cases since 2019. Although several vaccines have been certified by the WHO and people are being vaccinated on a global scale, it has been reported that multiple SARS-CoV-2 variants can escape neutralization by antibodies, resulting in vaccine breakthrough infections. Bacillus Calmette-Guérin (BCG) is known to induce heterologous protection based on trained immune responses. Here, we investigated whether BCG-induced trained immunity protected against SARS-CoV-2 in the K18-hACE2 mouse model. Our data demonstrate that i.v. BCG (BCG-i.v.) vaccination induces robust trained innate immune responses and provides protection against WT SARS-CoV-2, as well as the B.1.617.1 and B.1.617.2 variants. Further studies suggest that myeloid cell differentiation and activation of the glycolysis pathway are associated with BCG-induced training immunity in K18-hACE2 mice. Overall, our study provides the experimental evidence that establishes a causal relationship between BCG-i.v. vaccination and protection against SARS-CoV-2 challenge.
medicine, research & experimental